Articles related to Oncology Pharmacy (BCOP)

Tumor genomes may evolve during treatment as resistant subclones emerge under therapeutic pressure, prompting increasing use of comprehensive genomic profiling and serial ctDNA testing to inform ongoing precision oncology decisions.

A patient with PNH and persistent anemia during ravulizumab therapy experienced improved hemoglobin after danicopan was added, while an extended infusion delay highlighted treatment-continuity challenges without establishing protection from interrupted C5 inhibition.

Recent compensation surveys place average U.S. oncologist earnings between approximately $360,000 and $465,000 annually, with variation driven by subspecialty, geography, experience level, and persistent demographic pay disparities.

An updated review of multiple myeloma management highlights revised high-risk definitions, anti-CD38-based quadruplet induction regimens, evolving maintenance strategies, and increasing use of CAR-T and bispecific immunotherapies across the disease continuum.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

A patient with advanced, treatment-resistant lung cancer experienced complete tumor disappearance after sodium selenite treatment and remained tumor-free for 10 years. The single case cannot establish efficacy, safety, or causality.